Phase 1b HRX215 MKK4 inhibitor trial for post-hepatectomy metastatic colorectal cancer

This double-blind, randomized, placebo-controlled trial assesses the safety and pharmacokinetics of HRX215 in adults following liver surgery for metastatic colorectal cancer. Eligible participants include those undergoing either minor or major hepatectomy, with HRX215 compared to a placebo. The study, led by HepaRegeniX GmbH, represents an early test of an MKK4 inhibitor in this setting.